Framol-Med GmbH
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
At Framol-Med GmbH, the clinical research focus is centered on Respiratory Tract Diseases, with studies exploring both asthma and chronic obstructive pulmonary disease. The trials are designed to assess how well new and existing inhaled and biologic treatments can improve symptom control, reduce flare-ups, and support better long-term lung health.
- Evaluating combination inhaler therapies for better control of chronic breathing disorders
- Studying treatments aimed at reducing COPD exacerbations and related complications
- Assessing new options for asthma management in adolescents and adults
This research includes efforts to compare treatment effectiveness against standard care or placebo, helping clarify which approaches may offer the greatest benefit for patients with moderate-to-severe COPD and related respiratory conditions.
Chronic Obstructive Pulmonary Disease
The Pulmonology department at this hospital is conducting multiple trials focused on COPD, including more advanced forms of the disease. These studies are examining therapies intended to reduce worsening episodes, improve breathing outcomes, and address the needs of people living with persistent airway inflammation.
- Testing whether biologic therapies can lower the frequency of COPD attacks
- Comparing treatment strategies to improve cardiopulmonary outcomes
- Exploring new approaches for patients with type 2 inflammation and chronic airway disease
The overall goal is to generate clearer evidence on how emerging therapies may help patients with moderate-to-severe COPD achieve better disease control and quality of life.
Asthma
Research at Framol-Med GmbH also includes asthma, with trials looking at the effectiveness and safety of combination inhaled therapy. These studies aim to improve everyday symptom management and provide better options for people whose asthma remains difficult to control.
- Evaluating inhaled combination treatments for symptom relief and disease control
- Comparing active therapy with placebo to measure treatment benefit
- Supporting better care for adolescents and adults with persistent asthma
This area of research is focused on understanding whether newer treatment combinations can offer more effective control than current approaches while maintaining safety in routine respiratory care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 3 by active trials.
- 1AstraZeneca AB1active
lock +2 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Framol-Med GmbH
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 52-week, randomised, double blind, multicentre, 2-arm parallel group trial assessing the efficacy and safety of CHF6001 (total daily dose 3200 μg) Dry Powder Inhaler (DPI) add-on to maintenance medium or high dose inhaled corticosteroid in combination with long-acting ß2-agonists in subjects with uncontrolled asthma | Chiesi Farmaceutici S.p.A. | Phase II | Not Recruiting | Nov 2023 | Dec 2025 |
IMP list
lock Showing 1 of 10 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Salbutamol Sulfate | 2 | Unknown | 2025-07-22 | 2026-05-19 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
